Gland Pharma Announces Re-appointment of Independent Director Naina Lal Kidwai
Gland Pharma Limited confirmed the approval of the re-appointment of Ms. Naina Lal Kidwai as an Independent Director of the Company. The Board of Directors held a meeting on Thursday, April 09, 2026, to consider and approve this re-appointment.Ms. Kidwai, bearing DIN: 00017806, has been re-appointed for a second term spanning five consecutive years, effective from May 17, 2026, until May 16, 2031. This follows her initial appointment as an Independent Director for a five-year term from May 17, 2021, to May 16, 2026, as per Section 149 of the Companies Act, 2013.
The re-appointment is subject to the approval of the members, which the Company plans to obtain within stipulated timelines through a postal ballot and e-voting process.
A table summarizing the key details regarding Ms. Kidwai's re-appointment is provided below.
| Particulars | Detail |
|---|---|
| Independent Director | Ms. Naina Lal Kidwai (DIN: 00017806) |
| Re-appointment Period | Five consecutive years |
| Effective Date | May 17, 2026 till May 16, 2031 |
Professional Profile
Ms. Naina Lal Kidwai possesses an extensive professional background. She currently serves as the Chairman of Rothschild & Co India, and holds roles as a Senior Advisor for Advent Private Equity, a Senior Advisor for TPG Rise Climate, and a Venture Advisor for Lightspeed Venture Partners, India.Her directorship experience includes roles as a Non-Executive Director on the Boards of Holcim, Gland Pharma, UPL, and Biocon. Notably, she was the Past President of FICCI (Federation of Indian Chambers of Commerce & Industry). Her past senior roles include retiring as an Executive Director on the Board of HSBC Asia Pacific and Chairman of HSBC India in December 2015, and stepping down from the global Board of Nestle in April 2018.
Ms. Kidwai is also a member of the INDO-ASEAN Business Council, the Army Group Insurance Fund's investment advisory committee, Harvard Business School's South Asia Advisory Board, and the Standard Chartered Bank's International Advisory Council.
Academically, she holds an MBA from Harvard Business School and is the recipient of the Padma Shri for her contributions to Trade and Industry. Her professional interests span the environment, water, and sanitation sectors. She has authored three books, including the bestsellers '30 women in Power: Their Voices, Their Stories' and 'Survive Or Sink: An Action Agenda for Sanitation, Water, Pollution, and Green Finance'.
Her industry involvement includes chairing the Primary Markets Advisory Committee of SEBI and serving on various governmental and industry task forces such as the Government of India's Industry Task Force and the Prime Minister's Trade and Industry Council. Her current engagements reflect her focus on sustainability and empowerment, including Chair roles at FICCI's Water Mission and FICCI's Sustainability Council, and positions at the India Sanitation Coalition.
GLAND Stock Price Movement
Today, Gland Pharma Limited shares gained 0.96% in post-market trading, settling at ₹1749.1. The equity recorded a total trading volume of 31,364 shares during the session, marking its upward move.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.